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ABSTRACT: The anticoagulant rodenticides were discovered in the 1940s and their advantages of efficacy and safety 
quickly resulted in their use dominating the practice of rodent control in temperate countries. However, the development of 
resistance to the early compounds within a decade stimulated research culminating in the invention of anew class of anticoagu-
lant, the second generation compounds, active against resistant strains but also overall far more potent than those previously 
available. A novel baiting strategy, pulsed baiting, was developed to make full use of this valuable characteristic. Pulsed baiting 
has enabled the use of second generation anticoagulants in situations where early products were of limited value, particularly in 
tropical agriculture. The future of this highly-successful group of compounds is reviewed in relation to resistance and the 
difficulty and cost of developing further rodenticides. 
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INTRODUCTION 
Few modern pesticide groups have such long a history of 
successful use as the anticoagulant rodenticides. Their origin 
lies in the discovery that dicoumarin was the active agent 
responsible for a haemorrhagic condition found in the USA 
in cattle that had been fed spoiled sweet clover hay (Link 
1944). 
Early interest in anticoagulants was concentrated upon 
their therapeutic use for the treatment of thrombosis. Workers 
at the Wisconsin Alumni Research Foundation were respon-
sible for the isolation of dicoumarin and for the synthesis of a 
number of analogues in an attempt to increase the potency 
of the parent compound. The 42nd member of this series, 
subsequently called warfarin, proved to be the most active. 
The rodenticidal potential of these compounds seems to 
have been recognised independently in the USA and in the 
UK. According to Mills (1955), Link noted that warfarin 
"might make a good exterminating agent" following the ob-
servation that laboratory rodents died of haemorrhage. In the 
UK, workers researching dicoumarin had made a similar ob-
servation. When contacted by a pest controller who was un-
able to obtain rodenticides due to post-war shortages, they 
handed over a sample for trial. The first controlled trials be-
ing carried out in London in 1946-47. 
The unpublished reports of these trials and O'Connor 
(1948) indicate that the significant advantages of anticoagu-
lants over previously available rodenticides were recognised 
remarkably quickly. In an eighteen-month period, the foun-
dations were laid upon which all subsequent developments 
took place. 
Dicoumarin was introduced as a commercial rodenticidc 
in the UK in 1949 and warfarin was registered for sale in 
the USA in 1950. Because of its greater potency, warfarin 
superseded dicoumarin and very rapidly became the domi-
nant rodenticide, a position it was to retain on a world scale 
for many years. 
THE MODE OF ACTION OF 
ANTICOAGULANTS 
The anticoagulants represented a significant advance be-
cause they overcame nearly all of the negative aspects of their 
predecessors, the acute poisons. In order to understand why 
this should be it is necessary to understand the mode of action 
of anticoagulants. 
When the carcass of an anticoagulated rodent is analysed, 
by far the largest residue of anticoagulant is found in the liver, 
the site of action. Within the liver, Vitamin K is utilised to 
drive the production of blood clotting factors II, VII, IX & X 
by the gamma-carboxylation of glutamic acid residues of pre-
cursor proteins. Concomitant with this reaction, the active 
form of vitamin K, a hydroquinone (KHj), is converted to an 
inactive 2,3-epoxide. Some of this is excreted but the major-
ity is reactivated by an epoxide reductase enzyme. The reacti-
vated vitamin recycles and represents the major source of 
vitamin K in the clotting factor synthesis cycle. Small losses 
are replaced from extraneous sources, gut bacteria and from 
food (Fig. 1). 
Figure 1. The relationship between the metabolism and the 
physiological action of Vitamin K1. (After Park 1982). 
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All available anticoagulants seem to share the same site 
of action; they block the epoxide reductase enzyme 
(Silverman 1980). The recycling of activated vitamin K is 
therefore stopped and there is insufficient incoming vitamin 
K to maintain the carboxylation reaction. The production of 
clotting factors is critically reduced and eventually, when the 
supply of factors already present has degraded, the clotting 
mechanism fails and haemorrhaging begins. 
Because the mechanism is common to them all, there is 
no significant difference in the time to death between antico-
agulants once the enzyme is blocked. What can differ is the 
time taken to achieve this. Also, once more because of their 
common mode of action, the anticoagulants do not differ in 
the sites at which the lethal haemorrhages occur. 
The treatment of poisoning in the case of an accident is 
also common to all compounds. The synthesis of clotting 
factors can be restarted by the addition of appropriate amounts 
of Vitamin K4. Frequent administration is necessary until the 
anticoagulant has cleared. Different anticoagulants require 
different treatment periods dependent upon their half-lives at 
the site of action, varying from some hours for warfarin to 
several weeks for the more potent products (Anon. 1988, 
MacKintoshetal. 1988). 
THE ADVANTAGES OF ANTICOAGULANTS 
With an understanding of the mode of action of antico-
agulants, it is worth reviewing the advantages that were so 
quickly recognised by the early workers. These were, and still 
are, the reasons why the anticoagulant group of rodenticides 
came to dominate the practice of rodent control. 
Prior to the introduction of anticoagulants, the only com-
pounds available were fast-acting single-dose toxicants, such 
as thallium sulphate, red squill, arsenic, zinc phosphide, and 
the first purpose-built rodenticide, ANTU. 
Each suffered one common fault, they produced symp-
toms very rapidly. Rodent behaviour is such that an indi-
vidual encountering a new food for the first time will normally 
test feed and may not take a substantial quantity for many 
hours, or even days (Buckle et al. 1987). If the bait causes 
distressing symptoms during the test feeding period, the ro-
dent is intelligent enough to recognise cause and effect and 
becomes 'poison' or 'bait shy.' 
The only way to reduce the impact of bait shyness is to 
prebait for several days with unpoisoned bait base and then to 
substitute toxic bait when rodents have accepted the new 
food. Effective prebaiting requires considerable persistence, 
expertise and effort. 
The potency of the acute rodenticides varied consider-
ably, with their LD50's ranging between 5 and 100 mg/kg. In 
order to ensure a lethal intake in a single feed, the concentra-
tions of active ingredient in bails had to be high, normally 
between 0.5 and 5%. The early compounds had little if any 
selective toxicity and the high concentrations utilised meant 
that baits represented a considerable hazard to non-target spe-
cies. This problem was further exacerbated by the fact that 
few had an effective antidote and their speed of effect made 
treatment impractical even if one had been available. These 
considerations have lead to the imposition of rigorous 
restrictions on the use of acute rodenticides in many coun-
tries. The only one now widely used is zinc phosphide. 
In the case of anticoagulants, the delay between the 
ingestion of a potentially lethal dose and the onset of symp- 
toms is such that the rodent does not recognise their relation-
ship. In addition, the effect itself is relatively painless in most 
cases. Bait shyness does not occur, prebaiting is unnecessary, 
and compared to most other toxicants, anticoagulants may be 
considered relatively humane (Rowsell et al. 1979). 
Furthermore, a practical treatment was available in the 
event of accidental ingestion and, because of their potency, 
even the earliest could be used at concentrations more appro-
priately measured in parts per million (ppm), and therefore 
palatability was inherently far less of a problem than it had 
been with the fast-acting products. 
THE DEVELOPMENT OF ANTICOAGULANTS 
Commercial anticoagulant rodenticides are either indane-
diones or hydroxycoumarins, with the exception of one 
thiocoumarin. Following the introduction of warfarin, a num-
ber of compounds were developed during the nineteen fifties 
and these are now collectively known as the "first generation 
anticoagulants." Principal amongst these were the 
hydroxycoumarins, coumachlor (1951), coumafuryl (1953) 
and coumatetralyl (1956). Amongst the indane-diones were 
diphacinone (1952) and chlorophacinone (1961). Pindone 
was first developed as an insecticide and its rodenticidal 
properties were not utilised until 1953. A common feature of 
the first generation compounds is that they are chronic toxi-
cants: they are more potent if administered in small daily 
doses than if given as a single dose. For example the acute 
oral LD50 in rats of warfarin is variously quoted at between 
10-20 mg/kg (Lund 1982) and 323 mg/kg (Hagan and 
Radom-ski 1953). The sub-acute oral LD50 by contrast is 
generally accepted to be about 5 daily doses of 1 mg/kg for 
warfarin and for most of the first generation products. The 
reason for this apparent anomaly appears to relate to their 
half-lives. Yacobi and Wingard (1972) determined the bio-
logical half-life of warfarin in Sprague-Dawley rats as being 
between 5 and 28 hours. Warfarin is relatively easily detoxi-
fied by the action of mixed-function oxidase enzymes and 
converted to lower toxicity and easily excreted hydroxylated 
metabolites (Barker et al. 1969). In order to maintain an ef-
fective concentration at the active site it is necessary con-
stantly to renew anticoagulant removed by the action of these 
enzymes. 
The compounds discussed above came to dominate the 
practice of rodent control world-wide in the period 1950-
1965. They were used to such effect that it is perhaps not 
surprising that resistance genes should be selected. 
RESISTANCE TO FIRST GENERATION 
ANTICOAGULANTS 
Warfarin resistance was discovered first in Rattus 
norvegicus in the UK (Boyle 1960), then in Denmark, the 
Netherlands, the United States, Germany and France. Resis-
tance was also detected in Mus domesticus (Rowe and Red-
fern 1965) and in Rattus rattus (Greaves et al. 1976). Concern 
increased when it was found that cross-resistance existed to 
all first generation anticoagulants (Rowe and Redfern 1965, 
Greaves and Ayres 1969, Hadler and Shadbolt 1975). 
The occurrence of resistance in all of the major commen-
sal species to all of the anticoagulants then available rekindled 
research in an area which had been dormant as a consequence 
of the commercial dominance of these products. Greaves and 
Ayres (1969) showed that, in a Welsh strain of resistant 
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Table 1. No-choice feeding of anticoagulant to groups of 
house mice for up to 21 days. 
Table 2. 10-day no-choice feeding tests of anticoagulants 
against homozygons Welsh resistant Norway rats. 
 
 
R. norvegicus, the resistance gene is single, dominant and 
autosomal. Hermodson et al. (1969) showed that rats of this 
strain, homozygous for resistance, have a dietary requirement 
for vitamin K of twenty times normal. This suggested a 
change of an acceptor site on the reductase enzyme such that 
affinity to Vitamin K was reduced. 
Unpublished work with the 2-chloro analogue of vitamin 
K1 (Lowenthal and MacFarlane 1967), indicated that this 
known anticoagulant was not resisted, in fact it was more 
active against resistant individuals. This indicated the possi-
bility of producing analogues which would block the resistant 
enzyme and that the acceptor site corresponding to the 3-
phytyl side chain of vitamin K1 had not been modified. 
Consideration of the structures of a number of failed 
anti-malarial agents which had some anticoagulant activity 
suggested that the stable substituted 3-biphenyl side chains 
of these vitamin K-like l:4-naphthoquinones could be 
mimicking the 3-phytyl side-chain of vitamin K. 
SECOND GENERATION ANTICOAGULANTS 
Substitution of stereochemically similar side-chains onto 
the 4-hydroxycoumarin moiety produced a series of com-
pounds which was both effective against resistant strains and 
considerably more potent than any previously used anti-co-
agulant (Hadler and Shadbolt 1975). 
Two compounds were selected from the series for devel-
opment, difenacoum and brodifacoum. These were the first 
commercially available 'second generation anticoagulants.' 
The term was coined to describe compounds effective against 
strains resistant to previously available products. Difenacoum 
was first registered in the UK in 1975, followed by 
brodifacoum in 1978. Tables 1 and 2 illustrate the compara-
tive potencies of these two compounds compared with that of 
first generation products in resistant house mice and Norway 
rats. 
Meanwhile, in 1967, workers in France had synthesized 
a series of warfarin alcohol analogues with similar side-chain 
substitutions, although activity against resistant strains was 
not apparently recognised until one of these, bromadiolone, 
was introduced in France in 1978 (Grand 1976). 
Since the introduction of difenacoum, brodifacoum and 
bromadiolone, two further compounds, flocoumafen and 
difethiolone, have been added to the list of commercially 
available second generation anticoagulants. Apart from their 
ability to control rodents resistant to previously available an-
ticoagulants, the second generation products are characterised 
by their higher overall potency (Table 3). The acute oral 
toxicity of second generation products can be of the order of 
100 times greater than that of their predecessors. 
A PRACTICAL PATTERN OF USE FOR THE   
SECOND GENERATION ANTICOAGULANTS-
PULSED BAITING 
The first generation products were described as chronic 
rodenticides because several consecutive and substantial daily 
feeds of poisoned bait were required to deliver a lethal dose. 
This characteristic makes it necessary, when using them, to 
maintain large quantities of bait at the site of treatment, often 
for some weeks, and to visit the site frequently to replace 
eaten bait to ensure the continuous availability of rodenticide. 
This technique is known as surplus, or saturation, baiting 
(Dubock 1984). 
As well as activity against resistant rodents, the second 
generation anticoagulants possess another highly advanta-
geous characteristic. They are so potent that a lethal dose can 
be delivered when an animal consumes bait on a single occa-
sion and as only a fraction of its daily food requirement. For 
example, an adult R. norvegicus will consume about 20-30 
grammes of food daily and an adult M. musculus typically 2-
5 grammes. Thus, 0.005% brodifacoum bait will deliver an 
LD50 dose to a rat in only 1.3 grammes of bait and to a mouse 
in only 0.2 grammes. 
These observations, based on laboratory experiments 
(e.g. Redfern et al. 1976), led to speculation that brodifacoum 
could be potentially effective as a 'single application' roden-
ticide (Rennison and Dubock 1978). Trials were therefore 
conducted with brodifacoum baits against Norway rats on 
UK farms to test the efficacy of single bait applications of 1,4 
and 7 days duration. Contrary to expectations, complete con-
trol was not achieved with any of these regimens. They 
resulted in 41, 51 and 68% mortality respectively. It was 
concluded that, to achieve satisfactory levels of control, bait 
must be available for longer than a seven-day period because, 
clearly, a proportion of rats do not feed sufficiently from bait 
points in the first week to acquire a lethal dose. It was also 
concluded that those rats that took bait during the first week, 
and succumbed, were likely to have fed on several occasions 
thereby consuming more bait than necessary to cause death. 
These considerations gave rise to the concept of ‘pulsed 
baiting’ (Dubock 1984) in which limited quantities of bait are 
applied at approximately weekly intervals. Those animals 
that feed during the early stages of the treatment consume the 
available bait completely, finding none left when they return 
to the bait points subsequently. They die before another appli-
cation, or ‘pulse,’ of bait is laid for those animals that are 
more reluctant to begin feeding on the poison. Two or more 
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Table 3. Acute oral LD50 of active ingredients and baits of several anticoagulants 
against Norway rats and house mice. (After Dubock 1979). 
 
 
additional pulses may be required to achieve complete con-
trol of rat and mouse infestations. The mechanism of this 
process was displayed during field trials of one of the more 
recently introduced highly-potent second generation antico-
agulants, flocoumafen (Buckle 1985). 
The comparative performance of three compounds, 
difenacoum, bromadiolone and brodifacoum, in pulsed bait-
ing programmes was compared by Greaves et al. (1988). 
These authors found that treatment efficacy was directly 
related to the toxicity of the baits used. Thus, fewer bailing 
rounds and less bait was required to achieve complete control 
of resistant R. norvegicus infestations with brodifacoum baits 
than with baits containing either difenacoum or bromadiolone. 
The use of pulsed baiting with compounds such as 
brodifacoum and flocoumafen offers valuable advantages to 
the rodent control practitioner. Firstly, relatively small quan-
tities of bait are required and less labour is needed to apply it 
during baiting programmes, resulting in lower treatment costs. 
Also, for periods during treatments, no bait is exposed be-
cause it has all been consumed by the target rodents (Buckle 
1985), thus reducing the primary hazards of the treatment. 
There is also a reduction in the quantity of bait eaten by 
rodents resulting in reduced levels of residues in targets and 
potentially lower secondary non-target hazard (Dubock 
1984). 
This system is now in use in rodent control world-wide 
and is integral to the labeled use patterns of the second gen-
eration compounds. It is particularly applicable in agricul-
ture. Smallholders cultivating tropical field crops were always 
unwilling to employ the saturation baiting technique neces-
sary to ensure the full efficacy of the first generation antico-
agulants and consequently these compounds were never 
widely used in tropical agriculture. Similarly, the technique 
of prebaiting was never widely accepted in the use of the 
acute compounds, resulting in their frequent failure (e.g. West 
et al. 1972). Thus, until the introduction of the second gen-
eration compounds, tropical smallholders never had available 
to them a rodenticide bait and pattern of use appropriate to 
their needs. Field trials have now been conducted world-wide 
to develop safe and efficient patterns of use for these products 
in a very wide range of agricultural crops (e.g. Kaukeinen and 
Rampaud 1986, Hoque and Olvida 1988). 
SAFETY IN USE 
One of the major potential benefits of the anticoagulant 
rodenticides over their acute predecessors was that of 
improved safety. The features which lead to this are, in 
particular, the presence of an antidote, Vitamin K1, and the 
slow mode of action which provides adequate time in cases of 
accidental poisoning for diagnosis and treatment (Anon. 
1988). 
However, in spite of these safety features, as with all 
pesticides, the use of anticoagulants carries with it a degree of 
risk, particularly because this class of compounds contains 
potent mammalian toxophores. An exacerbating factor is the 
frequently commensal nature of the rodent pest problem, 
which means that rodenticides are often applied peri-
domestically, where accidental exposures to man and his 
companion and domestic animal are likely. Additionally, 'rat 
poisons' are attractive to those who would mis-use them as 
vertebrate killing agents outside labeled use patterns and for 
unlawful purposes unrelated to rodent control. 
In spite of all these factors, the anticoagulant rodenti-
cides have a remarkable history of safe and efficient use over 
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a period exceeding 40 years. Few published records exists 
which place this history into context but, perhaps, the most 
fully documented evidence on accidental exposure to harm-
ful substances is published in the USA. Litovitz et al. (1989) 
record that, of more than one million human exposures, only 
3.8% were associated with pesticides; a category which in-
cludes rodenticides as only a minor component. Exposures to 
analgesics, cleaning agents and cosmetics by far exceed in 
number exposures to pesticides. 
Although the number of exposures to rodenticides is 
relatively small, the demographic profile of these incidents is 
of great interest to those attempting to develop even safer 
products. The data presented by Litovitz et al. (1989) is typi-
cal in showing that the vast majority of exposures are via the 
oral route, involve children under the age of six and occur, 
presumably, when they accidentally encounter rodenticide 
bait placements. A major advance in ensuring a favourable 
outcome in such cases is the use of a human taste deterrent in 
rodenticidal preparations (Johnson 1988). This substance, 
‘Bitrex,’ is not perceived by rodents but its inclusion in bails 
at an appropriate concentration renders them highly objec-
tionable to humans (Kaukeinen and Buckle, these Proceed-
ings). This will serve to reduce the quantity of bait ingested 
during accidental exposures, although the numbers of 
recorded exposures may actually increase when baits contain 
'Bitrex' because their unpleasant taste will more likely cause 
'consumers' to report the episode. 
Companion animals are also occasionally exposed to ro-
denticides because of the often close association between the 
places where they are housed and the sites of rodent 
infestation. Care in bait placement, the use of bait stations of 
suitable construction and baits with low intrinsic palatability 
to companion animals will serve to reduce the frequency and 
severity of these exposures to very low levels but it is 
impossible to eliminate this risk altogether. 
ENVIRONMENTAL IMPACT 
It is unlikely that anticoagulant rodenticides will have 
any major adverse environmental impact (Kaukeinen 1982). 
Their mode of use generally involves the localised place-
ment, often within bait containers, of small quantities of bait 
with very low toxicant loadings. The contamination of either 
aquatic or soil systems with these compounds remains there-
fore a remote possibility envisaged only in the event of seri-
ous mis-use. 
However, the most problematic aspect of the potential of 
anticoagulants to have an impact is the hazard they may pose 
to animals that prey upon poisoned rodents or scavenge their 
dead bodies. All the second-generation compounds arc 
equally persistent, and even some of the earlier compounds 
are retained in animal tissues at sub-lethal levels for relatively 
long periods (Parmar et al. 1987, Huckle et al. 1989). It is 
known, therefore, that where target rodents are the dietary 
mainstay of a carnivorous non-target species, individuals of 
the latter species may be at risk (e.g., Hegdal and Colvin 
1988). To date, however, there is no indication that the occa-
sional mortalities caused by anticoagulants have had any af-
fect on non-target populations, as such losses are rapidly made 
good by breeding (Kaukeinen 1982, North 1985). 
One of the most thoroughly investigated interactions is 
that between Barn owls and anticoagulant rodenticides in the 
UK. In spite of the prolonged and intensive use of com- 
pounds such as coumatetralyl, difenacoum, bromadiolone and 
brodifacoum, there is no evidence that this has been to the 
detriment of Barn Owl populations (Percival, 1990). 
However, there is scope for studies to monitor the population 
levels of non-target animals, particularly predatory birds, and 
for the development of potent anticoagulants that are more 
rapidly eliminated from animal tissues than those currently 
available. 
THE FUTURE 
Five highly potent second generation anticoagulants have 
been commercialised and three of them, brodifacoum, 
flocoumafen and difethiolone, each to a greater or lesser ex-
tent, can be said to possess the capability of killing rodents 
after a single feed. These three compounds have acute oral 
LD50S to R. norvegicus in the range 0.2-0.4 mg/kg. It is the 
experience of one of us (MRH), having worked with numer-
ous experimental analogues, that none with significantly 
higher toxicity has ever been found. It appears that, after 45 
years of development of anticoagulants with progressively 
greater potency, the upper limit has at last been reached. 
Although the chronic action of the anticoagulant rodenti-
cides is an advantage in preventing the development of bait 
shyness, it also has the disadvantage that animals which have 
consumed a lethal dose of poison may continue to feed on 
bait for several subsequent days. This is both wasteful and 
increases secondary hazard. It would be beneficial to have a 
potent anticoagulant which caused death after, say, 2-3 days 
rather than the 5-6 days that is characteristic of the presently 
available compounds. However, the onset of symptoms of 
anticoagulation and death occurs only after the reservoir of 
various blood clotting factors have been fully depleted. This 
mechanism is fundamental to the mode of action of all com-
pounds and it seems, at the moment, unlikely that an antico-
agulant with a faster action can be produced. 
Several of the second-generation anticoagulants have 
been used extensively world-wide for 15 years or more. This 
constitutes a substantial selection pressure favouring the 
emergence of resistant strains. So far, however, resistance to 
these compounds is very localised. In southern-central En-
gland populations of R. norvegicus resistant to difenacoum are 
found in a locality coincident with a long- established area of 
warfarin resistance (Greaves et al. 1982). Resistance to both 
difenacoum and bromadiolone is present in Norway rats in 
Denmark (Lund 1984) and the Danish Pest Infestation labo-
ratory has also identified populations of House mice resistant 
to the same compounds (Anon. 1990). In both foci it is pos-
sible, in laboratory tests, to demonstrate that rodents are less 
sensitive to the more potent compound brodifacoum (e.g. Gill 
and MacNicoll 1991), although this altered level of tolerance 
falls short of resistance in practical terms. 
There is much speculation on what the future holds in 
terms of resistance to the second generation anticoagulants. 
Some workers feel that the levels of resistance described 
above presage the development of ever more resistant popu-
lations of rodents. There is an alternative view, however, that 
resistance may have reached an upper limit in the levels pres-
ently observed in southern England (Greaves and Cullen-
Ayres 1988). This is because possession of resistance genes 
carries with it the cost of impaired ability to synthesize Vita-
min K. Some resistant rodents require twenty times more 
dietary Vitamin K than their susceptible counterparts and 
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further development of resistance may thus be physiologi-
cally self-limiting. Whatever the future holds for resistance in 
temperate countries where anticoagulant use is intensive, it 
seems unlikely that resistance to the second generation com-
pounds will become a serious practical problem in the trop-
ics. This is implied by the fact that resistance to the first 
generation compounds, widespread in North America and in 
many European countries, is of very limited importance 
elsewhere. 
Given that anticoagulants are designed to be mammalian 
toxicants, their record of safety in use is impressive. Signifi-
cant selective toxicity has been achieved in favour of many 
non-target animals (Dubock and Kaukeinen 1978, Bowler et 
al. 1984, Lechevin and Poche 1988) but there would still 
seem to be a benefit in developing a product with even greater 
specificity. However, the increasingly rigourous regulatory 
requirements currently being introduced in the USA, Europe 
and elsewhere have caused companies to direct resources 
towards the defense of existing compounds rather than to the 
development of new ones. Furthermore, development costs 
have soared. For example, the cost of introducing 
flocoumafen during the 1980s was more than ten times 
greater, in real terms, than that of developing difenacoum a 
decade earlier. These costs, and the existence already of five 
highly potent compounds, would make it necessary to con-
sider carefully the commercial justification for the develop-
ment of a new, more specific anticoagulant, even if such a 
compound was technically feasible. 
Anticoagulant rodenticides have a long history of effec-
tive and safe use world-wide. It seems likely that those 
currently available will continue to dominate the practice of 
rodent control for many years to come. 
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